PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Jun 18 2025

0mins

TCRT+0.63%

Should l Buy TCRT?

Source: Globenewswire

PMGC Capital's Urging of Alaunos Therapeutics: PMGC Capital LLC has publicly urged Alaunos Therapeutics to accept a financing term sheet facilitated by a leading Wall Street bank, emphasizing that it represents a significant opportunity for the company and its shareholders.
Commitment to Shareholder Value: PMGC Capital remains dedicated to collaborating with Alaunos' leadership to enhance long-term shareholder value while commending the company's prudent financial management during challenging market conditions.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy TCRT?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on TCRT

About TCRT

Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Alaunos Therapeutics Reveals Promising ALN1003 Preclinical Data

2 hours agoBenzinga

Significant Drug Effects: Alaunos Therapeutics' ALN1003 demonstrated a mean weight loss of up to -12.9% in diet-induced obesity mouse studies, indicating potential as a new treatment option for obesity.
Liver Health Improvement: The drug reduced liver weight by 43% compared to untreated mice, highlighting its effectiveness and potential to lower the risk of obesity-related liver diseases.
Biochemical Indicator Improvement: Long-term administration of ALN1003 was associated with significant reductions in ALT, AST, and ALP levels, along with a trend toward lower total bilirubin, suggesting its potential in improving metabolic health.
Future Development Plans: The company plans to pursue additional financing to support ongoing preclinical work for ALN1003 and optimize manufacturing processes, ensuring drug efficacy and safety to pave the way for future IND applications.

Alaunos' ALN1003 Drug Candidate Shows Weight Loss Potential

8 hours agoNewsfilter

Significant Weight Loss: In the DIO mouse model, ALN1003-treated mice exhibited an average weight reduction of -12.9%, indicating the drug's potential efficacy in obesity treatment.
Liver Health Improvement: ALN1003 reduced liver weight by 43% and lowered liver injury biomarkers such as ALT and AST, suggesting a positive impact on metabolic-associated liver disease.
Reduced Food and Water Intake: The ALN1003 treatment group consumed significantly less food (347.5g/cage vs 425.0g/cage), which may correlate with the drug's weight loss mechanism, further supporting its potential as a non-hormonal treatment.
Ongoing R&D Plans: Alaunos is focused on conducting additional preclinical studies and optimizing manufacturing processes to advance ALN1003, aiming to provide a new non-hormonal treatment option for obesity patients.

4 Biotech Stocks Experiencing Decline: Momentum Scores Diminishing in the Last Week

Sep 03 2025Benzinga

Biotech Stocks Momentum Decline: Several biotech stocks have experienced significant declines in their Momentum scores over the past week, indicating a loss of strength in the sector.
Key Companies Affected: Notable companies like Capricor Therapeutics, Lava Therapeutics, Alaunos Therapeutics, and Champions Oncology have all reported drops in their Momentum scores due to various factors, including regulatory setbacks, financial losses, and downgrades from analysts.